Evaluating Cost-Effectiveness of First-Line Immune Checkpoint Inhibition in Melanoma
For treatment of BRAF wild-type, stage IV melanoma, first-line immune checkpoint inhibition is more cost-effective than chemotherapy.
For treatment of BRAF wild-type, stage IV melanoma, first-line immune checkpoint inhibition is more cost-effective than chemotherapy.
There are still many gaps in behavioral research, for skin cancer control.
SK-like melanoma are hard to diagnose, however dermoscopic features can help diagnose them.